OBJECTIVE: The aim of this study was to investigate the preliminary safety and efficacy of three doses of budiodarone in patients with paroxysmal atrial fibrillation. BACKGROUND:Budiodarone is a chemical analogue of amiodarone and shares its mixed ion channel electrophysiological properties. It has a shorter half-life than amiodarone. METHODS:Patients with paroxysmal atrial fibrillation and a previously implanted dual-chamber pacemaker capable of storing electrograms for at least 4 weeks were enrolled. Pacemaker memories were used to quantify atrial tachycardia/atrial fibrillation burden (AT/AFB). All antiarrhythmic drugs were stopped for greater than five half-lives and amiodarone greater than 3 months prior to enrollment. Following a 4-week baseline period to assess AT/AFB off antiarrhythmic drugs, patients with AT/AFB between 3% and 70% were blindly randomized to placebo, 200, 400, or 600 mg BID of budiodarone for 12 weeks followed by a 4-week washout period. Pacemakers were interrogated and safety assessed every 4 weeks. Pacemaker-derived electrograms were adjudicated blinded to treatment assignment. The primary study endpoint was percent change from baseline AT/AFB over 12 weeks of treatment compared to placebo. RESULTS: Of 72 randomized patients, 61 completed the study. The median reduction of AT/AFB for the 400 and 600 mg BID groups vs. placebo was 54% and 74% (p = 0.01 and 0.001), respectively. The budiodarone dose-response was statistically significant (p < 0.001). Number and duration of AT/AF episodes were reduced. CONCLUSIONS: In this preliminary study, budiodarone at both higher doses significantly reduced AT/AFB. The study is novel because dual-chamber pacemakers, previously placed for standard clinical indications, were successfully used to monitor AT/AFB.
RCT Entities:
OBJECTIVE: The aim of this study was to investigate the preliminary safety and efficacy of three doses of budiodarone in patients with paroxysmal atrial fibrillation. BACKGROUND:Budiodarone is a chemical analogue of amiodarone and shares its mixed ion channel electrophysiological properties. It has a shorter half-life than amiodarone. METHODS:Patients with paroxysmal atrial fibrillation and a previously implanted dual-chamber pacemaker capable of storing electrograms for at least 4 weeks were enrolled. Pacemaker memories were used to quantify atrial tachycardia/atrial fibrillation burden (AT/AFB). All antiarrhythmic drugs were stopped for greater than five half-lives and amiodarone greater than 3 months prior to enrollment. Following a 4-week baseline period to assess AT/AFB off antiarrhythmic drugs, patients with AT/AFB between 3% and 70% were blindly randomized to placebo, 200, 400, or 600 mg BID of budiodarone for 12 weeks followed by a 4-week washout period. Pacemakers were interrogated and safety assessed every 4 weeks. Pacemaker-derived electrograms were adjudicated blinded to treatment assignment. The primary study endpoint was percent change from baseline AT/AFB over 12 weeks of treatment compared to placebo. RESULTS: Of 72 randomized patients, 61 completed the study. The median reduction of AT/AFB for the 400 and 600 mg BID groups vs. placebo was 54% and 74% (p = 0.01 and 0.001), respectively. The budiodarone dose-response was statistically significant (p < 0.001). Number and duration of AT/AF episodes were reduced. CONCLUSIONS: In this preliminary study, budiodarone at both higher doses significantly reduced AT/AFB. The study is novel because dual-chamber pacemakers, previously placed for standard clinical indications, were successfully used to monitor AT/AFB.
Authors: P Dorian; W Jung; D Newman; M Paquette; K Wood; G M Ayers; J Camm; M Akhtar; B Luderitz Journal: J Am Coll Cardiol Date: 2000-10 Impact factor: 24.094
Authors: Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns Journal: N Engl J Med Date: 2002-12-05 Impact factor: 91.245
Authors: Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz Journal: N Engl J Med Date: 2005-05-05 Impact factor: 91.245
Authors: Lars Køber; Christian Torp-Pedersen; John J V McMurray; Ole Gøtzsche; Samuel Lévy; Harry Crijns; Jan Amlie; Jan Carlsen Journal: N Engl J Med Date: 2008-06-19 Impact factor: 91.245
Authors: Jonathan S Steinberg; Ara Sadaniantz; Jack Kron; Andrew Krahn; D Marty Denny; James Daubert; W Barton Campbell; Edward Havranek; Katherine Murray; Brian Olshansky; Gearoid O'Neill; Magdi Sami; Stanley Schmidt; Randle Storm; Miguel Zabalgoitia; John Miller; Mary Chandler; Elaine M Nasco; H Leon Greene Journal: Circulation Date: 2004-03-29 Impact factor: 29.690
Authors: Carsten W Israel; Gerian Grönefeld; Joachim R Ehrlich; Yi-Gang Li; Stefan H Hohnloser Journal: J Am Coll Cardiol Date: 2004-01-07 Impact factor: 24.094
Authors: Michael D Ezekowitz; Kenneth A Ellenbogen; John P DiMarco; Karoly Kaszala; Alexander Boddy; Gregory P Geba; Gregory Geba P; Andrew Koren Journal: J Interv Card Electrophysiol Date: 2015-02-01 Impact factor: 1.900